The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia
Abstract
Purpose: Dasatinib is a BCR-ABL inhibitor, 325-fold more potent than imatinib against unmutated BCR-ABL in vitro. Phase II studies have demonstrated efficacy and safety with dasatinib 70 mg twice daily in chronic-phase (CP) chronic myelogenous leukemia (CML) after imatinib treatment failure. In phase I, responses occurred with once-daily administration despite only intermittent BCR-ABL inhibition. Once-daily treatment resulted in less toxicity, suggesting that toxicity results from continuous inhibition of unintended targets. Here, a dose- and schedule-optimization study is reported. Patients and Methods: In this open-label phase III trial, 670 patients with imatinib-resistant or -intolerant CP-CML were randomly assigned 1:1:1:1 between four dasatinib treatment groups: 100 mg once daily, 50 mg twice daily, 140 mg once daily, or 70 mg twice daily. Results: With minimum follow-up of 6 months (median treatment duration, 8 months; range, < 1 to 15 months), marked and comparable hematologic (complete, 86% to 92%) and cytogenetic (major, 54% to 59%; complete, 41% to 45%) response rates were observed across the four groups. Time to and duration of cytogenetic response were similar, as was progression-free survival (8% to 11% of patients experienced disease progression or died). Compared with the approved 70-mg twice-daily regimen, dasatinib 100 mg once daily resulted in significantly lower rates of pleural effusion (all grades, 7% v 16%; P = .024) and grade 3 to 4 thrombocytopenia (22% v 37%; P = .004), and fewer patients required dose interruption (51% v 68%), reduction (30% v 55%), or discontinuation (16% v 23%). Conclusion: Dasatinib 100 mg once daily retains the efficacy of 70 mg twice daily with less toxicity. Intermittent target inhibition with tyrosine kinase inhibitors may preserve efficacy and reduce adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Self-citationO'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036
Self-citationRanson, M., Hammond, L. A., Ferry, D., Kris, M., Tullo, A., Murray, P. I., Miller, V., Averbuch, S., Ochs, J., Morris, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.112 · Cited by 763
Tokarski, J. S., Newitt, J. A., Chang, C. Y. J., Cheng, J. D., Wittekind, M., Kiefer, S. E., Kish, K., Lee, F. Y. F., Borzillerri, R., Lombardo, L. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4187 · Cited by 700
Burris, H. A., Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K. L., O'Neil, B., Marcom, P. K., Ellis, M. J., Overmoyer, B., Jones, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.584 · Cited by 619
Hochhaus, A., Kantarjian, H. M., Baccarani, M., Lipton, J. H., Apperley, J. F., Druker, B. J., Facon, T., Goldberg, S. L., Cervantes, F., Niederwieser, D., et al. (2007) · Blood · doi:10.1182/blood-2006-09-047266 · Cited by 609
Self-citationStrumberg, D., Clark, J. W., Awada, A., Moore, M. J., Richly, H., Hendlisz, A., Hirte, H. W., Eder, J. P., Lenz, H.-J., & Schwartz, B. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-426 · Cited by 419
Cortes, J., Rousselot, P., Kim, D.-W., Ritchie, E., Hamerschlak, N., Coutre, S., Hochhaus, A., Guilhot, F., Saglio, G., Apperley, J., et al. (2007) · Blood · doi:10.1182/blood-2006-09-046888 · Cited by 416
Self-citationKantarjian, H., Pasquini, R., Hamerschlak, N., Rousselot, P., Holowiecki, J., Jootar, S., Robak, T., Khoroshko, N., Masszi, T., Skotnicki, A., et al. (2007) · Blood · doi:10.1182/blood-2006-11-056028 · Cited by 377
Self-citation
Cited by
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Self-citationBaccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291
Self-citationA Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Self-citationTranslation of the Philadelphia chromosome into therapy for CML
Druker, B. J. (2008) · Blood · doi:10.1182/blood-2008-07-077958 · Cited by 668
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2018) · Blood · doi:10.1182/blood-2016-09-739086 · Cited by 592
Self-citationResponse and Resistance to BCR-ABL1-Targeted Therapies
Braun, T. P., Eide, C. A., & Druker, B. J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.006 · Cited by 483
Steegmann, J. L., Baccarani, M., Breccia, M., Casado, L. F., García-Gutiérrez, V, Hochhaus, A., Kim, D.-W., Kim, T. D., Khoury, H. J., Le Coutre, P., et al. (2016) · Leukemia · doi:10.1038/leu.2016.104 · Cited by 482
Self-citationCortes, J. E., Kim, D.-W., Kantarjian, H. M., Brümmendorf, T. H., Dyagil, I., Griskevicius, L., Malhotra, H., Powell, C., Gogat, K., Countouriotis, A. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7522 · Cited by 466
Self-citationCortes, J. E., Kantarjian, H. M., Brümmendorf, T. H., Kim, D.-W., Turkina, A. G., Shen, Z.-X., Pasquini, R., Khoury, H. J., Arkin, S., Volkert, A., et al. (2011) · Blood · doi:10.1182/blood-2011-05-355594 · Cited by 463
Self-citationFoà, R., Vitale, A., Vignetti, M., Meloni, G., Guarini, A., De Propris, M. S., Elia, L., Paoloni, F., Fazi, P., Cimino, G., et al. (2011) · Blood · doi:10.1182/blood-2011-05-351403 · Cited by 462
Apperley, J. F. (2015) · The Lancet · doi:10.1016/s0140-6736(13)62120-0 · Cited by 381
Ravandi, F., O'Brien, S., Thomas, D., Faderl, S., Jones, D., Garris, R., Dara, S., Jorgensen, J., Kebriaei, P., Champlin, R., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261586 · Cited by 348
Self-citationUnderstanding, recognizing, and managing toxicities of targeted anticancer therapies
Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21184 · Cited by 331
Khoury, H. J., Cortes, J. E., Kantarjian, H. M., Gambacorti-Passerini, C., Baccarani, M., Kim, D.-W., Zaritskey, A., Countouriotis, A., Besson, N., Leip, E., et al. (2012) · Blood · doi:10.1182/blood-2011-11-390120 · Cited by 324
Self-citationRea, D., Nicolini, F. E., Tulliez, M., Guilhot, F., Guilhot, J., Guerci-Bresler, A., Gardembas, M., Coiteux, V., Guillerm, G., Legros, L., et al. (2017) · Blood · doi:10.1182/blood-2016-09-742205 · Cited by 317
Self-citationAn, X., Tiwari, A. K., Sun, Y., Ding, P.-R., Ashby, C. R., & Chen, Z.-S. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.04.016 · Cited by 309
A comprehensive review of protein kinase inhibitors for cancer therapy
Kannaiyan, R., & Mahadevan, D. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1527688 · Cited by 302
Müller, M. C., Cortes, J. E., Kim, D.-W., Druker, B. J., Erben, P., Pasquini, R., Branford, S., Hughes, T. P., Radich, J. P., Ploughman, L., et al. (2009) · Blood · doi:10.1182/blood-2009-04-214221 · Cited by 290
Self-citationVascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
Valent, P., Hadzijusufovic, E., Schernthaner, G.-H., Wolf, D., Rea, D., & le Coutre, P. (2015) · Blood · doi:10.1182/blood-2014-09-594432 · Cited by 283
Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Assouline, S., Etienne, G., Nicolini, F. E., le Coutre, P., Clark, R. E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00080-2 · Cited by 265
Self-citationCortes, J., Apperley, J., Lomaia, E., Moiraghi, B., Undurraga Sutton, M., Pavlovsky, C., Chuah, C., Sacha, T., Lipton, J. H., Schiffer, C. A., et al. (2021) · Blood · doi:10.1182/blood.2021012082 · Cited by 208
Self-citationDeRemer, D. L., Ustun, C., & Natarajan, K. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.014 · Cited by 172
Demetri, G. D., Lo Russo, P., MacPherson, I. R. J., Wang, D., Morgan, J. A., Brunton, V. G., Paliwal, P., Agrawal, S., Voi, M., & Evans, T. R. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0224 · Cited by 150
Wong, H., Choo, E. F., Alicke, B., Ding, X., La, H., McNamara, E., Theil, F.-P., Tibbitts, J., Friedman, L. S., Hop, C. E. C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0738 · Cited by 133
Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib
Levêque, D., Becker, G., Bilger, K., & Natarajan-Amé, S. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00872-4 · Cited by 90
Martyanov, V., Kim, G.-H. J., Hayes, W., Du, S., Ganguly, B. J., Sy, O., Lee, S. K., Bogatkevich, G. S., Schieven, G. L., Schiopu, E., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187580 · Cited by 71
Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment
Jabbour, E., Parikh, S. A., Kantarjian, H., & Cortes, J. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.09.004 · Cited by 68
Self-citationMasiello, D., Gorospe, G., & Yang, A. S. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-46 · Cited by 66
Murai, K., Ureshino, H., Kumagai, T., Tanaka, H., Nishiwaki, K., Wakita, S., Inokuchi, K., Fukushima, T., Yoshida, C., Uoshima, N., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00333-1 · Cited by 63
Lindauer, M., & Hochhaus, A. (2010) · Recent Results in Cancer Research · doi:10.1007/978-3-642-01222-8_7 · Cited by 57
Self-citationLa Rosée, P., Martiat, P., Leitner, A., Klag, T., Müller, M. C., Erben, P., Schenk, T., Saussele, S., & Hochhaus, A. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1769-2 · Cited by 50
“A dose optimization study confirmed this initial observation leading to modification of the initially approved treatment schedule in chronic phase (100 mg QD) as well as in accelerated phase (AP) and blast crisis (BC) (140 mg QD) [8, 9].”
BackgroundSelf-citationSharma, M. R., Wroblewski, K., Polite, B. N., Knost, J. A., Wallace, J. A., Modi, S., Sleckman, B. G., Taber, D., Vokes, E. E., Stadler, W. M., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9681-x · Cited by 49
Rousselot, P., Mollica, L., Guilhot, J., Guerci, A., Nicolini, F. E., Etienne, G., Legros, L., Charbonnier, A., Coiteux, V., Dartigeas, C., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17654 · Cited by 46
Self-citationFox, L. C., Cummins, K. D., Costello, B., Yeung, D., Cleary, R., Forsyth, C., Tatarczuch, M., Burbury, K., Motorna, O., Shortt, J., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016003889 · Cited by 43
Matsumura, I., Ohtake, S., Atsuta, Y., Kurata, M., Minami, Y., Takahashi, N., Nakaseko, C., Iriyama, N., Fujimaki, K., Kakihana, K., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012655 · Cited by 21
Kantarjian, H., Zhai, Y., Oehler, V. G., Jamy, O., Koller, P. B., Haddad, F. G., Sasaki, K., & Jabbour, E. J. (2025) · Cancer · doi:10.1002/cncr.35832 · Cited by 10
Self-citation
Metadata
- Authors
- Shah, N. P., Kantarjian, H. M., Kim, D.-W., Réa, D., Dorlhiac-Llacer, P. E., Milone, J. H., Vela-Ojeda, J., Silver, R. T., Khoury, H. J., Charbonnier, A., Khoroshko, N., Paquette, R. L., Deininger, M., Collins, R. H., Otero, I., Hughes, T., Bleickardt, E., Strauss, L., Francis, S., & Hochhaus, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-07-01
- Volume
- 26
- Issue
- 19
- Pages
- 3204-3212
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2116153687
- Cited by
- 489
- References
- 21
- FWCI
- 39.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.